secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001674930-26-000012
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 2.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics completes acquisitions of Bako Diagnostics and StrataDx for ~$56.9M cash
--------------------------------------------------------------------------------

- Total combined purchase price approximately $56.9 million in cash, subject to post-closing adjustments.
- StrataDx acquired for ~$13.5M cash; Bako Diagnostics assets acquired for ~$43.4M cash.
- Acquisition includes lease assignment for 29,099 sq ft lab/office in Alpharetta, GA through July 2032.
- Advisors: Piper Sandler and Mintz Levin for Fulgent; EV Health Partners and Latham & Watkins for sellers.
- Transaction originally announced Dec 22, 2025; closed March 17, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000167493026000012/0001674930-26-000012-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000167493026000012/flgt-20260317.htm
  HTML page:      https://secwatch.observer/filing/0001674930-26-000012

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer